[Case of MMF monotherapy for membranous nephropathy]

Mioko Kobayashi, Chiari Kojima, Hidekazu Sugiura, Asuka Aoki, Mitsuyo Itabashi, Misao Tsukada, Takashi Takei, Keiko Uchida, Kosaku Nitta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report the case of a 58-year-old male patient who visited our hospital for the management of edema and proteinuria. He was diagnosed as having nephrotic syndrome, with serum total protein and albumin levels of 4.6 g/dL and 2.1 g/dL, respectively, and a urinary protein excretion level of 6.0 g/day. A percutaneous renal biopsy showed features of membranous glomerulonephritis, with capillary-wall granular deposits of IgG and C3 on immunofluorescence and subepithelial immune complex deposits on electron microscopy. No other secondary cause of membranous glomerulopathy was found even after extensive investigations. The patient was started on mycophenolate mofetil (MMF) monotherapy (1,500 mg/day), and 18 months after the start of this therapy, the proteinuria decreased to 0.5 g/day, with return to a normal serum albumin level. No digestive symptoms, kidney function worsening or increase in blood pressure were noted during treatment. These findings suggest that MMF monotherapy is effective and safe for the treatment of membranous nephropathy.

Original languageEnglish (US)
Pages (from-to)572-577
Number of pages6
JournalNihon Jinzo Gakkai shi
Volume52
Issue number5
StatePublished - 2010

Fingerprint

Mycophenolic Acid
Membranous Glomerulonephritis
Proteinuria
Serum Albumin
Kidney
Nephrotic Syndrome
Antigen-Antibody Complex
Fluorescent Antibody Technique
Blood Proteins
Edema
Electron Microscopy
Therapeutics
Immunoglobulin G
Blood Pressure
Biopsy
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kobayashi, M., Kojima, C., Sugiura, H., Aoki, A., Itabashi, M., Tsukada, M., ... Nitta, K. (2010). [Case of MMF monotherapy for membranous nephropathy]. Nihon Jinzo Gakkai shi, 52(5), 572-577.

[Case of MMF monotherapy for membranous nephropathy]. / Kobayashi, Mioko; Kojima, Chiari; Sugiura, Hidekazu; Aoki, Asuka; Itabashi, Mitsuyo; Tsukada, Misao; Takei, Takashi; Uchida, Keiko; Nitta, Kosaku.

In: Nihon Jinzo Gakkai shi, Vol. 52, No. 5, 2010, p. 572-577.

Research output: Contribution to journalArticle

Kobayashi, M, Kojima, C, Sugiura, H, Aoki, A, Itabashi, M, Tsukada, M, Takei, T, Uchida, K & Nitta, K 2010, '[Case of MMF monotherapy for membranous nephropathy]', Nihon Jinzo Gakkai shi, vol. 52, no. 5, pp. 572-577.
Kobayashi M, Kojima C, Sugiura H, Aoki A, Itabashi M, Tsukada M et al. [Case of MMF monotherapy for membranous nephropathy]. Nihon Jinzo Gakkai shi. 2010;52(5):572-577.
Kobayashi, Mioko ; Kojima, Chiari ; Sugiura, Hidekazu ; Aoki, Asuka ; Itabashi, Mitsuyo ; Tsukada, Misao ; Takei, Takashi ; Uchida, Keiko ; Nitta, Kosaku. / [Case of MMF monotherapy for membranous nephropathy]. In: Nihon Jinzo Gakkai shi. 2010 ; Vol. 52, No. 5. pp. 572-577.
@article{99cc992405c84201a6d69d0120362964,
title = "[Case of MMF monotherapy for membranous nephropathy]",
abstract = "We report the case of a 58-year-old male patient who visited our hospital for the management of edema and proteinuria. He was diagnosed as having nephrotic syndrome, with serum total protein and albumin levels of 4.6 g/dL and 2.1 g/dL, respectively, and a urinary protein excretion level of 6.0 g/day. A percutaneous renal biopsy showed features of membranous glomerulonephritis, with capillary-wall granular deposits of IgG and C3 on immunofluorescence and subepithelial immune complex deposits on electron microscopy. No other secondary cause of membranous glomerulopathy was found even after extensive investigations. The patient was started on mycophenolate mofetil (MMF) monotherapy (1,500 mg/day), and 18 months after the start of this therapy, the proteinuria decreased to 0.5 g/day, with return to a normal serum albumin level. No digestive symptoms, kidney function worsening or increase in blood pressure were noted during treatment. These findings suggest that MMF monotherapy is effective and safe for the treatment of membranous nephropathy.",
author = "Mioko Kobayashi and Chiari Kojima and Hidekazu Sugiura and Asuka Aoki and Mitsuyo Itabashi and Misao Tsukada and Takashi Takei and Keiko Uchida and Kosaku Nitta",
year = "2010",
language = "English (US)",
volume = "52",
pages = "572--577",
journal = "Nihon Jinzo Gakkai shi",
issn = "0385-2385",
publisher = "Japanese Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - [Case of MMF monotherapy for membranous nephropathy]

AU - Kobayashi, Mioko

AU - Kojima, Chiari

AU - Sugiura, Hidekazu

AU - Aoki, Asuka

AU - Itabashi, Mitsuyo

AU - Tsukada, Misao

AU - Takei, Takashi

AU - Uchida, Keiko

AU - Nitta, Kosaku

PY - 2010

Y1 - 2010

N2 - We report the case of a 58-year-old male patient who visited our hospital for the management of edema and proteinuria. He was diagnosed as having nephrotic syndrome, with serum total protein and albumin levels of 4.6 g/dL and 2.1 g/dL, respectively, and a urinary protein excretion level of 6.0 g/day. A percutaneous renal biopsy showed features of membranous glomerulonephritis, with capillary-wall granular deposits of IgG and C3 on immunofluorescence and subepithelial immune complex deposits on electron microscopy. No other secondary cause of membranous glomerulopathy was found even after extensive investigations. The patient was started on mycophenolate mofetil (MMF) monotherapy (1,500 mg/day), and 18 months after the start of this therapy, the proteinuria decreased to 0.5 g/day, with return to a normal serum albumin level. No digestive symptoms, kidney function worsening or increase in blood pressure were noted during treatment. These findings suggest that MMF monotherapy is effective and safe for the treatment of membranous nephropathy.

AB - We report the case of a 58-year-old male patient who visited our hospital for the management of edema and proteinuria. He was diagnosed as having nephrotic syndrome, with serum total protein and albumin levels of 4.6 g/dL and 2.1 g/dL, respectively, and a urinary protein excretion level of 6.0 g/day. A percutaneous renal biopsy showed features of membranous glomerulonephritis, with capillary-wall granular deposits of IgG and C3 on immunofluorescence and subepithelial immune complex deposits on electron microscopy. No other secondary cause of membranous glomerulopathy was found even after extensive investigations. The patient was started on mycophenolate mofetil (MMF) monotherapy (1,500 mg/day), and 18 months after the start of this therapy, the proteinuria decreased to 0.5 g/day, with return to a normal serum albumin level. No digestive symptoms, kidney function worsening or increase in blood pressure were noted during treatment. These findings suggest that MMF monotherapy is effective and safe for the treatment of membranous nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=84923649057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923649057&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 572

EP - 577

JO - Nihon Jinzo Gakkai shi

JF - Nihon Jinzo Gakkai shi

SN - 0385-2385

IS - 5

ER -